Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/BeOne Medicines Ltd./ 8-K

Current Report · Items 2.02, 9.01 · 8-K

BeOne Medicines Ltd.

Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 5, 2026, BeOne Medicines Ltd. announced its financial results for the three months ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

Filed Nov 5, 2026Accepted Nov 5, 2026, 6:04 AM ESTCIK 1651308Accession 0001628280-26-070469
View company →Permanent SEC source ↗
Share

Press release in this filing

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates →

Company context

Current securities

BEIGFOTC · EQUITY · CurrentONCNASDAQ · ADR · Current

Recent company filings

  1. 10-Q filingNov 5, 2026
  2. 144 filingSep 8, 2026
  3. Results of Operations and Financial ConditionAug 26, 2026
  4. 144 filingAug 25, 2026
  5. 144 filingAug 25, 2026

Registered securities in this filing

BEONE MEDICINES LTD. · 8-K · Filed 2026-11-05

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share

Symbol
ONC
Exchange
NASDAQ
Classification
ADS
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000162828026070469 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition. On November 5, 2026, BeOne Medicines Ltd. announced its financial results for the three months ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.